There is currently no effective therapy for patients with advanced HLRCC-associated papillary renal cell carcinoma. Treatment with bevacizumab and erlotinib resulted in a confirmed response of 72% in ...
Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC) is a rare, autosomal dominant syndrome characterised by the development of cutaneous and uterine leiomyomas alongside an aggressive form of ...
Rurality and screening colonoscopy participation in patients with Lynch syndrome. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text ...
(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a managing advanced disease in renal and rare cancer session and a Society of Urologic Oncology (SUO) lecture ...
We are continuing to see an increase in the incidence of kidney cancer in younger patients over time. Maintaining kidney health involves basic lifestyle choices: avoiding obesity, not smoking, and ...
The PET tracer [ 89 Zr]Zr-girentuximab targets carbonic anhydrase IX (CAIX), a hypoxia-inducible enzyme that is strongly expressed in clear cell renal cell carcinoma (ccRCC). CAIX expression is highly ...
This is a prospective study of all patients with metastatic RCC unselected for high-risk features, registered at our center between September 2023 and August 2024. Baseline clinicopathologic details ...
Incidental detection has increased with ubiquitous CT/MRI, inflating early-stage ‘small renal mass’ diagnoses and complicating interpretation of a ~5% rise in <50-year incidence. Obesity, hypertension ...
Many medicines are available to treat kidney cancer. If one treatment doesn’t help or stops working, your health care provider may recommend another option. If you or a loved one has kidney cancer and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results